Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 70 entries
Sorted by: Best Match Show Resources per page
Improving physician's adherence to completing vaccination schedules for patients with type 2 diabetes attending non-communicable diseases clinics in West Bay Health Center, Qatar.

BMJ quality improvement reports

Tawfik H, Bashwar Z, Al-Ali A, Salem M, Abdelbagi I.
PMID: 26732463
BMJ Qual Improv Rep. 2015 Sep 15;4(1). doi: 10.1136/bmjquality.u208497.w3388. eCollection 2015.

Incomplete vaccination for patients with type 2 diabetes attending non-communicable diseases (NCD) clinics is an issue that could affect patient's health and wellness negatively and puts patients at high risk of serious diseases. We aimed to improve physicians adherence...

Cite
Tawfik H, Bashwar Z, Al-Ali A, et al. Improving physician's adherence to completing vaccination schedules for patients with type 2 diabetes attending non-communicable diseases clinics in West Bay Health Center, Qatar. BMJ Qual Improv Rep. 2015;4(1)doi: 10.1136/bmjquality.u208497.w3388.
Tawfik, H., Bashwar, Z., Al-Ali, A., Salem, M., & Abdelbagi, I. (2015). Improving physician's adherence to completing vaccination schedules for patients with type 2 diabetes attending non-communicable diseases clinics in West Bay Health Center, Qatar. BMJ quality improvement reports, 4(1), . https://doi.org/10.1136/bmjquality.u208497.w3388
Tawfik, Hassan, et al. "Improving physician's adherence to completing vaccination schedules for patients with type 2 diabetes attending non-communicable diseases clinics in West Bay Health Center, Qatar." BMJ quality improvement reports vol. 4,1 (2015). doi: https://doi.org/10.1136/bmjquality.u208497.w3388
Tawfik H, Bashwar Z, Al-Ali A, Salem M, Abdelbagi I. Improving physician's adherence to completing vaccination schedules for patients with type 2 diabetes attending non-communicable diseases clinics in West Bay Health Center, Qatar. BMJ Qual Improv Rep. 2015 Sep 15;4(1). doi: 10.1136/bmjquality.u208497.w3388. eCollection 2015. PMID: 26732463; PMCID: PMC4693091.
Copy Download .nbib Format: NLM
The association between dental and periodontal diseases and sickle cell disease. A pilot case-control study.

The Saudi dental journal

Al-Alawi H, Al-Jawad A, Al-Shayeb M, Al-Ali A, Al-Khalifa K.
PMID: 25544813
Saudi Dent J. 2015 Jan;27(1):40-3. doi: 10.1016/j.sdentj.2014.08.003. Epub 2014 Nov 27.

OBJECTIVE: This is a pilot case-control study conducted to investigate the prevalence of dental caries and periodontal disease and examine the possible association between oral health deterioration and SCD severity in a sample of Saudi SCD patients residing in...

Cite
Al-Alawi H, Al-Jawad A, Al-Shayeb M, et al. The association between dental and periodontal diseases and sickle cell disease. A pilot case-control study. Saudi Dent J. 2014;27(1):40-3doi: 10.1016/j.sdentj.2014.08.003.
Al-Alawi, H., Al-Jawad, A., Al-Shayeb, M., Al-Ali, A., & Al-Khalifa, K. (2015). The association between dental and periodontal diseases and sickle cell disease. A pilot case-control study. The Saudi dental journal, 27(1), 40-3. https://doi.org/10.1016/j.sdentj.2014.08.003
Al-Alawi, Haidar, et al. "The association between dental and periodontal diseases and sickle cell disease. A pilot case-control study." The Saudi dental journal vol. 27,1 (2015): 40-3. doi: https://doi.org/10.1016/j.sdentj.2014.08.003
Al-Alawi H, Al-Jawad A, Al-Shayeb M, Al-Ali A, Al-Khalifa K. The association between dental and periodontal diseases and sickle cell disease. A pilot case-control study. Saudi Dent J. 2015 Jan;27(1):40-3. doi: 10.1016/j.sdentj.2014.08.003. Epub 2014 Nov 27. PMID: 25544813; PMCID: PMC4273253.
Copy Download .nbib Format: NLM
Adrenal Mass in Patients who Underwent Abdominal Computed Tomography Examination.

North American journal of medical sciences

Al-Thani H, El-Menyar A, Al-Sulaiti M, ElGohary H, Al-Malki A, Asim M, Tabeb A.
PMID: 26110133
N Am J Med Sci. 2015 May;7(5):212-9. doi: 10.4103/1947-2714.157482.

BACKGROUND: Adrenal masses are usually discovered incidentally (IAM) during abdominal computed tomography (CT).AIMS: We aimed to describe the prevalence, management, and outcome of incidentally discovered adrenal mass on radiological investigation.MATERIALS AND METHODS: A retrospective analysis was conducted to look...

Cite
Al-Thani H, El-Menyar A, Al-Sulaiti M, et al. Adrenal Mass in Patients who Underwent Abdominal Computed Tomography Examination. N Am J Med Sci. 2015;7(5):212-9doi: 10.4103/1947-2714.157482.
Al-Thani, H., El-Menyar, A., Al-Sulaiti, M., ElGohary, H., Al-Malki, A., Asim, M., & Tabeb, A. (2015). Adrenal Mass in Patients who Underwent Abdominal Computed Tomography Examination. North American journal of medical sciences, 7(5), 212-9. https://doi.org/10.4103/1947-2714.157482
Al-Thani, Hassan, et al. "Adrenal Mass in Patients who Underwent Abdominal Computed Tomography Examination." North American journal of medical sciences vol. 7,5 (2015): 212-9. doi: https://doi.org/10.4103/1947-2714.157482
Al-Thani H, El-Menyar A, Al-Sulaiti M, ElGohary H, Al-Malki A, Asim M, Tabeb A. Adrenal Mass in Patients who Underwent Abdominal Computed Tomography Examination. N Am J Med Sci. 2015 May;7(5):212-9. doi: 10.4103/1947-2714.157482. PMID: 26110133; PMCID: PMC4462817.
Copy Download .nbib Format: NLM
Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities.

Leukemia research

Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A.
PMID: 26410460
Leuk Res. 2015 Sep 03; doi: 10.1016/j.leukres.2015.09.001. Epub 2015 Sep 03.

The prognostic impact of combined NPM1+/FLT3- genotype is not well defined in elderly patients with acute myeloid leukemia (AML), and in the setting of different treatments, such as cytotoxic chemotherapy (Chemo), hematopoietic cell transplantation (HCT), or hypomethylating agents (HMA)....

Cite
Hefazi M, Siddiqui M, Patnaik M, et al. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015;doi: 10.1016/j.leukres.2015.09.001.
Hefazi, M., Siddiqui, M., Patnaik, M., Wolanskyj, A., Alkhateeb, H., Zblewski, D., Elliott, M., Hogan, W., Litzow, M., & Al-Kali, A. (2015). Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leukemia research, . https://doi.org/10.1016/j.leukres.2015.09.001
Hefazi, Mehrdad, et al. "Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities." Leukemia research vol. (2015). doi: https://doi.org/10.1016/j.leukres.2015.09.001
Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015 Sep 03; doi: 10.1016/j.leukres.2015.09.001. Epub 2015 Sep 03. PMID: 26410460.
Copy Download .nbib Format: NLM
Improving documentation of cardiovascular disease risk in patients with diabetes attending non communicable disease clinics at West Bay Health Center in Qatar.

BMJ quality improvement reports

Salem M, Al-Ali A, Bashwar Z.
PMID: 26734364
BMJ Qual Improv Rep. 2015 Mar 25;4(1). doi: 10.1136/bmjquality.u207778.w3190. eCollection 2015.

The documentation of cardiovascular disease (CVD) in medical records of patients with type 2 diabetes attending non communicable disease (NCD) clinics at West Bay Health Center in Qatar is less than ideal. Poor documentation of CVD will lead to...

Cite
Salem M, Al-Ali A, Bashwar Z. Improving documentation of cardiovascular disease risk in patients with diabetes attending non communicable disease clinics at West Bay Health Center in Qatar. BMJ Qual Improv Rep. 2015;4(1)doi: 10.1136/bmjquality.u207778.w3190.
Salem, M., Al-Ali, A., & Bashwar, Z. (2015). Improving documentation of cardiovascular disease risk in patients with diabetes attending non communicable disease clinics at West Bay Health Center in Qatar. BMJ quality improvement reports, 4(1), . https://doi.org/10.1136/bmjquality.u207778.w3190
Salem, Mohamed, et al. "Improving documentation of cardiovascular disease risk in patients with diabetes attending non communicable disease clinics at West Bay Health Center in Qatar." BMJ quality improvement reports vol. 4,1 (2015). doi: https://doi.org/10.1136/bmjquality.u207778.w3190
Salem M, Al-Ali A, Bashwar Z. Improving documentation of cardiovascular disease risk in patients with diabetes attending non communicable disease clinics at West Bay Health Center in Qatar. BMJ Qual Improv Rep. 2015 Mar 25;4(1). doi: 10.1136/bmjquality.u207778.w3190. eCollection 2015. PMID: 26734364; PMCID: PMC4645917.
Copy Download .nbib Format: NLM
Does Seasonality, Tidal Cycle, and Plumage Color Influence Feeding Behavior and Efficiency of Western Reef Heron (.

Animals : an open access journal from MDPI

Al-Ali A, Bin Muzaffar S, Hamza W.
PMID: 32110863
Animals (Basel). 2020 Feb 26;10(3). doi: 10.3390/ani10030373.

Polymorphic traits may evolve in many species of birds, often driven by multiple environmental factors. It is hypothesized that polymorphic traits in herons could be influenced by feeding behavior. Most of the Western Reef Herons (Egretta egularis) (more than...

Cite
Al-Ali A, Bin Muzaffar S, Hamza W. Does Seasonality, Tidal Cycle, and Plumage Color Influence Feeding Behavior and Efficiency of Western Reef Heron (. Animals (Basel). 2020;10(3)doi: 10.3390/ani10030373.
Al-Ali, A., Bin Muzaffar, S., & Hamza, W. (2020). Does Seasonality, Tidal Cycle, and Plumage Color Influence Feeding Behavior and Efficiency of Western Reef Heron (. Animals : an open access journal from MDPI, 10(3), . https://doi.org/10.3390/ani10030373
Al-Ali, Ahmed, et al. "Does Seasonality, Tidal Cycle, and Plumage Color Influence Feeding Behavior and Efficiency of Western Reef Heron (." Animals : an open access journal from MDPI vol. 10,3 (2020). doi: https://doi.org/10.3390/ani10030373
Al-Ali A, Bin Muzaffar S, Hamza W. Does Seasonality, Tidal Cycle, and Plumage Color Influence Feeding Behavior and Efficiency of Western Reef Heron (. Animals (Basel). 2020 Feb 26;10(3). doi: 10.3390/ani10030373. PMID: 32110863; PMCID: PMC7142541.
Copy Download .nbib Format: NLM
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

Blood cancer journal

Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W.
PMID: 33654067
Blood Cancer J. 2021 Mar 02;11(3):47. doi: 10.1038/s41408-021-00443-1.

No abstract available.

Cite
Hampel PJ, Parikh SA, Call TG, et al. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J. 2021;11(3):47doi: 10.1038/s41408-021-00443-1.
Hampel, P. J., Parikh, S. A., Call, T. G., Shah, M. V., Bennani, N. N., Al-Kali, A., Rabe, K. G., Wang, Y., Muchtar, E., Leis, J. F., Kenderian, S. S., Koehler, A. B., Schwager, S. M., Slager, S. L., Kay, N. E., Hanson, C. A., Van Dyke, D. L., Shi, M., & Ding, W. (2021). Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood cancer journal, 11(3), 47. https://doi.org/10.1038/s41408-021-00443-1
Hampel, Paul J, et al. "Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia." Blood cancer journal vol. 11,3 (2021): 47. doi: https://doi.org/10.1038/s41408-021-00443-1
Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J. 2021 Mar 02;11(3):47. doi: 10.1038/s41408-021-00443-1. PMID: 33654067; PMCID: PMC7925672.
Copy Download .nbib Format: NLM
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.

British journal of haematology

Gangat N, Guglielmelli P, Al-Kali A, Wolanskyj-Spinner AP, Camoriano J, Patnaik MM, Pardanani A, Hanson CA, Vannucchi AM, Tefferi A.
PMID: 34124793
Br J Haematol. 2021 Oct;195(1):133-137. doi: 10.1111/bjh.17626. Epub 2021 Jun 14.

No abstract available.

Cite
Gangat N, Guglielmelli P, Al-Kali A, et al. Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. Br J Haematol. 2021;195(1):133-137doi: 10.1111/bjh.17626.
Gangat, N., Guglielmelli, P., Al-Kali, A., Wolanskyj-Spinner, A. P., Camoriano, J., Patnaik, M. M., Pardanani, A., Hanson, C. A., Vannucchi, A. M., & Tefferi, A. (2021). Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. British journal of haematology, 195(1), 133-137. https://doi.org/10.1111/bjh.17626
Gangat, Naseema, et al. "Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women." British journal of haematology vol. 195,1 (2021): 133-137. doi: https://doi.org/10.1111/bjh.17626
Gangat N, Guglielmelli P, Al-Kali A, Wolanskyj-Spinner AP, Camoriano J, Patnaik MM, Pardanani A, Hanson CA, Vannucchi AM, Tefferi A. Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. Br J Haematol. 2021 Oct;195(1):133-137. doi: 10.1111/bjh.17626. Epub 2021 Jun 14. PMID: 34124793.
Copy Download .nbib Format: NLM
JAK2 wild type erythrocytosis associated with sodium-glucose cotransporter-2 inhibitor therapy.

Blood

Gangat N, Szuber N, Alkhateeb HB, Al-Kali A, Pardanani AD, Tefferi A.
PMID: 34653249
Blood. 2021 Oct 15; doi: 10.1182/blood.2021013996. Epub 2021 Oct 15.

No abstract available.

Cite
Gangat N, Szuber N, Alkhateeb HB, et al. JAK2 wild type erythrocytosis associated with sodium-glucose cotransporter-2 inhibitor therapy. Blood. 2021;doi: 10.1182/blood.2021013996.
Gangat, N., Szuber, N., Alkhateeb, H. B., Al-Kali, A., Pardanani, A. D., & Tefferi, A. (2021). JAK2 wild type erythrocytosis associated with sodium-glucose cotransporter-2 inhibitor therapy. Blood, . https://doi.org/10.1182/blood.2021013996
Gangat, Naseema, et al. "JAK2 wild type erythrocytosis associated with sodium-glucose cotransporter-2 inhibitor therapy." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021013996
Gangat N, Szuber N, Alkhateeb HB, Al-Kali A, Pardanani AD, Tefferi A. JAK2 wild type erythrocytosis associated with sodium-glucose cotransporter-2 inhibitor therapy. Blood. 2021 Oct 15; doi: 10.1182/blood.2021013996. Epub 2021 Oct 15. PMID: 34653249.
Copy Download .nbib Format: NLM
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Leukemia

Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U.
PMID: 34172893
Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25.

We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were...

Cite
Steensma DP, Wermke M, Klimek VM, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542-3550doi: 10.1038/s41375-021-01328-9.
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Ades, L., Al-Kali, A., Alonso-Dominguez, J. M., Alfonso-Piérola, A., Coombs, C. C., Deeg, H. J., Flinn, I., Foran, J. M., Garcia-Manero, G., Maris, M. B., McMasters, M., Micol, J. B., De Oteyza, J. P., Thol, F., Wang, E. S., Watts, J. M., Taylor, J., Stone, R., Gourineni, V., Marino, A. J., Yao, H., Destenaves, B., Yuan, X., Yu, K., Dar, S., Ohanjanian, L., Kuida, K., Xiao, J., Scholz, C., Gualberto, A., & Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 35(12), 3542-3550. https://doi.org/10.1038/s41375-021-01328-9
Steensma, David P, et al. "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms." Leukemia vol. 35,12 (2021): 3542-3550. doi: https://doi.org/10.1038/s41375-021-01328-9
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. PMID: 34172893; PMCID: PMC8632688.
Copy Download .nbib Format: NLM
A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States.

American journal of hematology

Ruan GJ, Smith CJ, Day C, Harmsen WS, Zblewski DL, Alkhateeb H, Begna K, Al-Kali A, Litzow MR, Hogan W, Gangat N, Patnaik MS, Pardanani A, Tefferi A, Go RS, Shah MV.
PMID: 32533865
Am J Hematol. 2020 Jun 13; doi: 10.1002/ajh.25906. Epub 2020 Jun 13.

No abstract available.

Cite
Ruan GJ, Smith CJ, Day C, et al. A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. Am J Hematol. 2020;doi: 10.1002/ajh.25906.
Ruan, G. J., Smith, C. J., Day, C., Harmsen, W. S., Zblewski, D. L., Alkhateeb, H., Begna, K., Al-Kali, A., Litzow, M. R., Hogan, W., Gangat, N., Patnaik, M. S., Pardanani, A., Tefferi, A., Go, R. S., & Shah, M. V. (2020). A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. American journal of hematology, . https://doi.org/10.1002/ajh.25906
Ruan, Gordon J, et al. "A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States." American journal of hematology vol. (2020). doi: https://doi.org/10.1002/ajh.25906
Ruan GJ, Smith CJ, Day C, Harmsen WS, Zblewski DL, Alkhateeb H, Begna K, Al-Kali A, Litzow MR, Hogan W, Gangat N, Patnaik MS, Pardanani A, Tefferi A, Go RS, Shah MV. A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. Am J Hematol. 2020 Jun 13; doi: 10.1002/ajh.25906. Epub 2020 Jun 13. PMID: 32533865.
Copy Download .nbib Format: NLM
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

Blood cancer journal

Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W.
PMID: 33654067
Blood Cancer J. 2021 Mar 02;11(3):47. doi: 10.1038/s41408-021-00443-1.

No abstract available.

Cite
Hampel PJ, Parikh SA, Call TG, et al. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J. 2021;11(3):47doi: 10.1038/s41408-021-00443-1.
Hampel, P. J., Parikh, S. A., Call, T. G., Shah, M. V., Bennani, N. N., Al-Kali, A., Rabe, K. G., Wang, Y., Muchtar, E., Leis, J. F., Kenderian, S. S., Koehler, A. B., Schwager, S. M., Slager, S. L., Kay, N. E., Hanson, C. A., Van Dyke, D. L., Shi, M., & Ding, W. (2021). Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood cancer journal, 11(3), 47. https://doi.org/10.1038/s41408-021-00443-1
Hampel, Paul J, et al. "Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia." Blood cancer journal vol. 11,3 (2021): 47. doi: https://doi.org/10.1038/s41408-021-00443-1
Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J. 2021 Mar 02;11(3):47. doi: 10.1038/s41408-021-00443-1. PMID: 33654067; PMCID: PMC7925672.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 70 entries